Shots:Minze Health has entered into a 3yr. agreement with Medtronic to commercialize its Minze Diary Pod, an automated bladder diary solution, across the EMEA regionPartnership will integrate the Diary Pod into the Sacral Neuromodulation (SNM) care pathway for pts with Overactive Bladder (OAB) receiving Medtronic’s InterStim therapy, allowing objective data collection during diagnosis…
Shots:The US FDA has approved the Altaviva device, an implantable tibial neuromodulation therapy to treat urge urinary incontinenceAltaviva device is placed under the skin above the fascia & near the ankle in a minimally invasive, sedation & imaging-free procedure to restore bladder–brain communication & improve bladder control by delivering electrical impulses to the tibial…
Shots:Medtronic has received CE mark to extend label of MiniMed 780G system to pts (≥2yrs.), pregnant women & T2D pts; application is under the FDA’s review for T2D, plus US trial for use in pts (2-6yrs.) is underwayApproval was backed by extensive clinical data incl. LENNY trial data in T1D pts (2–6 yrs), showing a…
Shots: Driven by continuous innovation, the MedTech sector is evolving rapidly to enhance preventive, diagnostic, and therapeutic capabilities in healthcareIn 2023, the global MedTech market was valued at $668.2B and is projected to reach $989.1B by 2033, growing at a CAGR of approximately 4%. Medtronic led the industry with a revenue of $33.12B, followed…
Shots: Bringing innovation and technology to healthcare, the MedTech sector is growing rapidly and transforming the ways diagnosis and treatment are received With a global market size of $503.2B in 2023, the MedTech sector anticipates reaching $776.4B by 2033 with a CAGR of 4.4 percent. With a staggering revenue of $32.31B, Medtronic ranks first in…
Shots:The second quarter of 2023 highlights multiple clinical trial results, approvals, and numerous deals. There are major alliances in this quarter which include Merck acquired Prometheus for ~$10.8B and Astellas entered into a definitive agreement to acquire Iveric Bio for ~$5.9BThe second quarter of the year also showcases multiple approvals of the therapies…
The year 2022 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements, clinical trial results and gaining approvals. Our team has compiled a list of 30 most read life sciences news on PharmaShots in 20221. AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to…
Shots:Robert spoke about the publication of the new study in the Heart Rhythm Journal about the Micra AV leadless pacemaker and how it is an effective therapy for patients with atrioventricular (AV) block Robert talked about the study design and the key findings from the study evaluating Medtronic’s Micra AV device The interview gives an understanding…
The third quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include CVS Health acquired Signify Health for ~$8B, Amgen acquired Chemocentryx for ~$4BThe third quarter of the year also showcases multiple approvals of the therapies which include Incyte's Opzelura US FDA's approval for Vitiligo,…
Despite the severe impact of the Covid-19 pandemic in 2020, the medical device market continued to emerge with patients' more significant needs and emerging diseases In 2021, the medical device markets continued to supply personal protective equipment for the pandemic and new technological developments. Medtronic remains at the top of the ledger with total revenue…

